Pre-Clinical

ReBio

ReBio is a pre-clinical stage biotechnology company that has developed SiSu®, a novel, proprietary injectable formulation technology that solves the safety and efficacy challenges other sustained release approaches have been unable to resolve. ReBio's SiSu® technology is a phase-inverting anhydrous liquid polymer platform that forms a semi-solid in-situ forming implant when injected into an aqueous environment. SiSu® is designed to steadily release effective levels of therapeutics within the eye by a combination of controlled diffusion of API molecules and API release via controlled hydrolysis (degradation) of the polymer into safe and non-toxic compounds that are well tolerated and naturally cleared from the body.